Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Ney A
Authors: Ney A, Al-Akkad W, Frenguelli L, Acedo P, Mazza G,
Keywords: 3d models, pancreatic neuroendocrine tumors, Biomarkers,
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: SCALORBI F
Authors: Scalorbi F, Mazzaglia S, Maccauro M, Chiesa C, Prinzi N,
Keywords: prrt, healthy tissue and target lesion dosimetry, gastroenteropancreatic neuroendocrine tumor,
Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Ferolla P, Berruti A, Fazio N, Mazzanti P, Houchard A,
Keywords: Temozolomide, lanreotide,
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: pusceddu s
Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,
Keywords: everolimus,
Introduction: CS is characterized by flushing, diarrhea and carcinoid heart disease (CHD) alone or in association.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Pusceddu S, Mazzaferro V, De Braud F, Coppa J, Milione M,
Keywords: carcinoid syndrome,